Acacia Pharma has announced the launch and commercial availability of Barhemsys® (amisulpride injection).

Barhemsys, a selective dopamine-2 and dopamine-3 receptor antagonist, is indicated for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class, and for the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. The approval was based on data from 4 double-blind, placebo-controlled trials evaluating the therapy for both prevention and treatment of PONV.

Barhemsys is supplied as 5mg/2mL solution in single-dose vials. It is administered via intravenous infusion over 1-2 minutes at the time of induction of anesthesia (PONV prevention) or in the event of nausea and vomiting after a surgical procedure (PONV treatment).

The use of Barhemsys should be avoided in patients with congenital long QT syndrome and in patients taking droperidol as the treatment can cause dose- and concentration-dependent prolongation of the QT interval. The most common adverse reactions associated with therapy include increased blood prolactin concentrations, chills, hypokalemia, procedural hypotension, abdominal distention and infusion site pain.


Continue Reading

“Barhemsys is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis with an agent of a different class using current standard of care and we estimate there are approximately 16 million such surgical patients each year in the US that go on to suffer from PONV despite receiving prophylaxis,” said Mike Bolinder, Acacia Pharma’s CEO. “We believe there will be strong demand for Barhemsys as US healthcare institutions seek to address surgical backlogs created by the coronavirus crisis and are very happy to make this new therapy available in the US.”

For more information visit barhemsys.com.

References

  1. Barhemsys® (amisulpride injection) launched in the US for the treatment and prevention of PONV. https://www.globenewswire.com/news-release/2020/08/24/2082317/0/en/BARHEMSYS-amisulpride-injection-Launched-in-the-US-for-the-Treatment-and-Prevention-of-PONV.html. Accessed August 24, 2020. 
  2. Barhemsys [package insert]. Indianapolis, IN: Acacia Pharma; 2020.

This article originally appeared on MPR